Selective serotonin re-uptake inhibitors : the clinical use of citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline
Author(s)
Bibliographic Information
Selective serotonin re-uptake inhibitors : the clinical use of citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline
(Perspectives in psychiatry, v. 1)
Wiley, c1991
Available at 3 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
Includes bibliographical references and index
Description and Table of Contents
Description
Over the past ten years, researchers have had the opportunity, at the Feighner Research Institute, to work with paroxetine, fluoxetine and other selective serotonin re-uptake inhibitors. They maintain that these drugs represent a significant addition in psychiatry because of their relative lack of side-effects and broad range of potential clinical indications. Indeed, their widespread and increasing use in the United States and other countries underlines this importance. This book reflects the state of the art in terms of the clinical issues surrounding these medications. The first chapter of the book reviews the evidence that points to the effects of these drugs on serotonergic function and the central role of serotonin in many psychiatric disorders, while the following chapter reviews the pharmacology of the selective serotonin re-uptake inhibitors. The remaining chapters contain reviews of clinical trials of the selective serotonin re-uptake inhibitors in many of the conditions previously mentioned, concluding with a chapter on important clinical issues in the use of these agents.
This book is aimed at all those who take care of depressed patients, but especially at residents and clinicians in psychiatry and general medicine. Clinicians are confronted daily with human suffering and require knowledge of what is both safe and effective for their patients. This is a different stance from that of the pure scientist, who accepts nothing as fact until replicated experimental evidence is available. Hence the purpose of this book is to review the available evidence from a clinical standpoint.
Table of Contents
- The neuropharmacology of serotonin in the central nervous system, C.A.Marsden
- the comparative pharmacological properties of selective serotonin re-uptake inhibitors in animals, A.M.Johnson
- the serotonin hypothesis - necessary but not sufficient, W.F.Boyer and J.P.Feighner
- pharmacokinetics and drug interactions, W.F.Boyer and J.P.Feighner
- the efficacy of selective serotonin re-uptake inhibitors in depression, W.F.Boyer and J.P.Feighner
- the efficacy of selective serotonin re-uptake inhibitors in anxiety and obsessive-compulsive disorder, W.F.Boyer et al
- other potential indications for selective serotonin re-uptake inhibitors, W.F.Boyer and J.P.Feighner
- side-effects of the selective serotonin re-uptake inhibitors, W.F.Boyer and J.P.Feighner
- clinical use of the selective serotonin re-uptake inhibitors, W.F.Boyer et al.
by "Nielsen BookData"